Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...

Vicero, Inc., a preclinical-stage biopharmaceutical company developing next-generation VINCOBODIES for immune-mediated ...

Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T cell ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Researchers discovered that an immunotherapy, called anti-CTLA-4, mobilizes microglia against glioblastoma as it causes CD4+ T cell infiltration of the brain. A study led by Salk Institute (CA, USA) ...

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called ...

Interestingly, CTLA-4 knockout mice and mice that lack expression of CTLA-4 just in T REG develop fatal, early-onset lymphoproliferative disease. 1,4 In addition, expression and signaling of CTLA ...

2 These proteins turn off the immune system and prevent it from killing cancer cells. Anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) and anti-programmed death-1 (anti-PD-1) drugs work by blocking ...

The oral presentation highlights translational data from the ongoing Phase 2 study evaluating botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1 ...

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...